Literature DB >> 26692443

Increased Expression of the Glucose Transporter Type 1 Gene Is Associated With Worse Overall Survival in Resected Pancreatic Adenocarcinoma.

Ashley H Davis-Yadley1, Andrea M Abbott, Jose M Pimiento, Dung-Tsa Chen, Mokenge P Malafa.   

Abstract

OBJECTIVES: There is currently no reliable method to predict the risk of relapse after curative resection of early-stage pancreatic adenocarcinoma. Increased glucose metabolism observed on F-fluorodeoxyglucose positron emission tomography (PET) by malignant cells, the Warburg effect, is a well-known characteristic of the malignant phenotype. We investigated the role of glucose transporter type 1 (GLUT-1) gene expression, a glucose cell plasma membrane transporter, in early-stage pancreatic cancer.
METHODS: Associations between GLUT-1 gene expression with PET maximum standardized uptake values and histologic grade were investigated in early-stage pancreatic adenocarcinoma patients. Multivariate analysis was conducted to determine predictors of prognosis. Cox proportional hazard model was used for survival analysis.
RESULTS: Sixty-three patients had GLUT-1 gene analysis performed, and 50 patients had both GLUT-1 analysis and PET scan. Patients with high GLUT-1 gene expression had a decreased overall survival by univariate analysis using Cox proportional hazard model (hazard ratio, 2.82; P = 0.001) and remained significant on multivariate analysis (hazard ratio, 2.54; P = 0.03). There was no correlation of GLUT-1 gene expression with histologic grade or PET maximum standardized uptake values.
CONCLUSIONS: Increased GLUT-1 gene expression was associated with a decreased overall survival in pancreatic adenocarcinoma. This supports increased GLUT-1 gene expression as a potential prognostic marker in resected pancreatic adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26692443      PMCID: PMC4912950          DOI: 10.1097/MPA.0000000000000580

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  38 in total

1.  Apoptosis and changes in glucose transport early after treatment of Morris hepatoma with gemcitabine.

Authors:  U Haberkorn; M E Bellemann; G Brix; H Kamencic; I Morr; U Traut; A Altmann; J Doll; J Blatter; R Kinscherf
Journal:  Eur J Nucl Med       Date:  2001-04

2.  On the origin of cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-02-24       Impact factor: 47.728

3.  GLUT-1 expression in pancreatic neoplasia: implications in pathogenesis, diagnosis, and prognosis.

Authors:  Olca Basturk; Rajendra Singh; Ecmel Kaygusuz; Serdar Balci; Nevra Dursun; Nil Culhaci; N Volkan Adsay
Journal:  Pancreas       Date:  2011-03       Impact factor: 3.327

4.  Glut 1 expression in transitional cell carcinoma of the urinary bladder is associated with poor patient survival.

Authors:  M Younes; D Juarez; L V Lechago; S P Lerner
Journal:  Anticancer Res       Date:  2001 Jan-Feb       Impact factor: 2.480

5.  Pancreatic metastasis detected by F-18 FDG PET/CT in a patient with breast cancer.

Authors:  Winnie Wing-Chuen Lam; Kelvin Siu-Hoong Loke; Hoi Yin Loi; Ajit Kumar Padhy
Journal:  Clin Nucl Med       Date:  2011-06       Impact factor: 7.794

6.  Apigenin inhibits the GLUT-1 glucose transporter and the phosphoinositide 3-kinase/Akt pathway in human pancreatic cancer cells.

Authors:  Laleh G Melstrom; Mohammad R Salabat; Xian-Zhong Ding; Benjamin M Milam; Matthew Strouch; Jill C Pelling; David J Bentrem
Journal:  Pancreas       Date:  2008-11       Impact factor: 3.327

7.  Histologic characteristics enhance predictive value of American Joint Committee on Cancer staging in resectable pancreas cancer.

Authors:  James Helm; Barbara A Centeno; Domenico Coppola; Marcovalerio Melis; Mark Lloyd; Jong Y Park; Dung-Tsa Chen; Mokenge P Malafa
Journal:  Cancer       Date:  2009-09-15       Impact factor: 6.860

8.  Preoperative staging of lung cancer with combined PET-CT.

Authors:  Barbara Fischer; Ulrik Lassen; Jann Mortensen; Søren Larsen; Annika Loft; Anne Bertelsen; Jesper Ravn; Paul Clementsen; Asbjørn Høgholm; Klaus Larsen; Torben Rasmussen; Susanne Keiding; Asger Dirksen; Oke Gerke; Birgit Skov; Ida Steffensen; Hanne Hansen; Peter Vilmann; Grete Jacobsen; Vibeke Backer; Niels Maltbaek; Jesper Pedersen; Henrik Madsen; Henrik Nielsen; Liselotte Højgaard
Journal:  N Engl J Med       Date:  2009-07-02       Impact factor: 91.245

9.  Glucose transporter-1 gene expression is associated with pancreatic cancer invasiveness and MMP-2 activity.

Authors:  Hiromichi Ito; Mark Duxbury; Michael J Zinner; Stanley W Ashley; Edward E Whang
Journal:  Surgery       Date:  2004-09       Impact factor: 3.982

10.  GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis.

Authors:  R S Haber; A Rathan; K R Weiser; A Pritsker; S H Itzkowitz; C Bodian; G Slater; A Weiss; D E Burstein
Journal:  Cancer       Date:  1998-07-01       Impact factor: 6.860

View more
  15 in total

Review 1.  Metabolic Barriers to T Cell Function in Tumors.

Authors:  Ayaka Sugiura; Jeffrey C Rathmell
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

Review 2.  Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies.

Authors:  Kristin G Anderson; Ingunn M Stromnes; Philip D Greenberg
Journal:  Cancer Cell       Date:  2017-03-13       Impact factor: 31.743

Review 3.  Power of two: combination of therapeutic approaches involving glucose transporter (GLUT) inhibitors to combat cancer.

Authors:  Kalpana Tilekar; Neha Upadhyay; Cristina V Iancu; Vadim Pokrovsky; Jun-Yong Choe; C S Ramaa
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-10-21       Impact factor: 10.680

4.  CD63 and GLUT-1 Overexpression Could Predict a Poor Clinical Outcome in GIST: A Study of 54 Cases with Follow-Up.

Authors:  Piotr Lewitowicz; Jarosław Matykiewicz; Dorota Koziel; Magdalena Chrapek; Agata Horecka-Lewitowicz; Stanislaw Gluszek
Journal:  Gastroenterol Res Pract       Date:  2016-10-04       Impact factor: 2.260

5.  Glucose transporter-1 as an independent prognostic marker for cancer: a meta-analysis.

Authors:  Zheng-Xiao Zhao; Lin-Wei Lu; Jian Qiu; Qiu-Ping Li; Fei Xu; Bao-Jun Liu; Jing-Cheng Dong; Wei-Yi Gong
Journal:  Oncotarget       Date:  2017-07-04

Review 6.  Novel Diagnostic and Predictive Biomarkers in Pancreatic Adenocarcinoma.

Authors:  John C Chang; Madappa Kundranda
Journal:  Int J Mol Sci       Date:  2017-03-20       Impact factor: 5.923

7.  Proteomic analyses identify prognostic biomarkers for pancreatic ductal adenocarcinoma.

Authors:  Dingyuan Hu; Daniel Ansari; Krzysztof Pawłowski; Qimin Zhou; Agata Sasor; Charlotte Welinder; Theresa Kristl; Monika Bauden; Melinda Rezeli; Yi Jiang; György Marko-Varga; Roland Andersson
Journal:  Oncotarget       Date:  2018-01-03

Review 8.  Fates of CD8+ T cells in Tumor Microenvironment.

Authors:  Nomathamsanqa Resegofetse Maimela; Shasha Liu; Yi Zhang
Journal:  Comput Struct Biotechnol J       Date:  2018-11-22       Impact factor: 7.271

Review 9.  Metabolic reprogramming and its clinical application in thyroid cancer.

Authors:  Shi-Shuai Wen; Ting-Ting Zhang; Di-Xin Xue; Wei-Li Wu; Yu-Long Wang; Yu Wang; Qing-Hai Ji; Yong-Xue Zhu; Ning Qu; Rong-Liang Shi
Journal:  Oncol Lett       Date:  2019-06-18       Impact factor: 2.967

Review 10.  Intrinsic and Extrinsic Determinants of T Cell Metabolism in Health and Disease.

Authors:  Haydn Munford; Sarah Dimeloe
Journal:  Front Mol Biosci       Date:  2019-10-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.